| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polymorphism, Single Nucleotide | 65 | 2023 | 552 | 4.710 |
Why?
|
| Genetic Predisposition to Disease | 44 | 2021 | 529 | 3.400 |
Why?
|
| Humans | 122 | 2023 | 4119 | 3.200 |
Why?
|
| Genome-Wide Association Study | 33 | 2022 | 417 | 2.460 |
Why?
|
| Haplotypes | 19 | 2023 | 122 | 2.210 |
Why?
|
| Male | 71 | 2023 | 1811 | 2.000 |
Why?
|
| Genotype | 37 | 2023 | 320 | 1.890 |
Why?
|
| Genetic Variation | 13 | 2021 | 189 | 1.850 |
Why?
|
| Genome, Human | 14 | 2023 | 104 | 1.750 |
Why?
|
| Genetics, Population | 8 | 2023 | 46 | 1.710 |
Why?
|
| Microsatellite Repeats | 8 | 2020 | 34 | 1.650 |
Why?
|
| Mutation | 12 | 2021 | 608 | 1.510 |
Why?
|
| Female | 59 | 2021 | 2147 | 1.510 |
Why?
|
| Chromosomes, Human, Y | 5 | 2020 | 6 | 1.510 |
Why?
|
| Models, Genetic | 11 | 2020 | 117 | 1.390 |
Why?
|
| Gene Frequency | 23 | 2023 | 120 | 1.300 |
Why?
|
| Software | 4 | 2023 | 133 | 1.290 |
Why?
|
| Eye Color | 4 | 2021 | 4 | 1.270 |
Why?
|
| Hair Color | 4 | 2021 | 4 | 1.270 |
Why?
|
| Genetic Markers | 17 | 2021 | 60 | 1.170 |
Why?
|
| Chromosome Mapping | 11 | 2016 | 146 | 1.140 |
Why?
|
| Sarcoidosis | 8 | 2012 | 11 | 0.980 |
Why?
|
| DNA Copy Number Variations | 4 | 2023 | 79 | 0.980 |
Why?
|
| Adult | 34 | 2021 | 944 | 0.930 |
Why?
|
| DNA | 7 | 2023 | 102 | 0.920 |
Why?
|
| DNA Fingerprinting | 5 | 2023 | 11 | 0.900 |
Why?
|
| Case-Control Studies | 29 | 2021 | 322 | 0.890 |
Why?
|
| Linkage Disequilibrium | 21 | 2020 | 92 | 0.850 |
Why?
|
| Computational Biology | 5 | 2018 | 164 | 0.840 |
Why?
|
| Genetic Linkage | 5 | 2019 | 46 | 0.830 |
Why?
|
| Chromosomes, Human, X | 4 | 2019 | 15 | 0.820 |
Why?
|
| Middle Aged | 30 | 2021 | 843 | 0.810 |
Why?
|
| Forensic Genetics | 6 | 2021 | 9 | 0.790 |
Why?
|
| Nuclear Proteins | 4 | 2016 | 83 | 0.780 |
Why?
|
| Phenotype | 14 | 2023 | 479 | 0.740 |
Why?
|
| Molecular Epidemiology | 1 | 2020 | 11 | 0.730 |
Why?
|
| Signal Transduction | 4 | 2018 | 261 | 0.730 |
Why?
|
| Algorithms | 5 | 2021 | 165 | 0.710 |
Why?
|
| Models, Biological | 1 | 2020 | 115 | 0.690 |
Why?
|
| Phylogeography | 1 | 2019 | 9 | 0.690 |
Why?
|
| Twins, Monozygotic | 1 | 2019 | 10 | 0.680 |
Why?
|
| Sequence Analysis, DNA | 10 | 2015 | 249 | 0.680 |
Why?
|
| DNA Methylation | 3 | 2020 | 186 | 0.680 |
Why?
|
| Indians, South American | 2 | 2020 | 3 | 0.660 |
Why?
|
| Alleles | 14 | 2018 | 221 | 0.640 |
Why?
|
| Germany | 19 | 2018 | 251 | 0.630 |
Why?
|
| Aggressive Periodontitis | 7 | 2013 | 10 | 0.600 |
Why?
|
| Membrane Proteins | 6 | 2018 | 101 | 0.600 |
Why?
|
| Europe | 11 | 2021 | 60 | 0.600 |
Why?
|
| Genetic Loci | 7 | 2020 | 120 | 0.600 |
Why?
|
| Founder Effect | 1 | 2016 | 5 | 0.590 |
Why?
|
| Nijmegen Breakage Syndrome | 1 | 2016 | 4 | 0.590 |
Why?
|
| Benchmarking | 2 | 2022 | 7 | 0.590 |
Why?
|
| Reproduction | 1 | 2016 | 12 | 0.590 |
Why?
|
| Skin Pigmentation | 3 | 2021 | 5 | 0.590 |
Why?
|
| Dermatitis, Atopic | 4 | 2009 | 10 | 0.580 |
Why?
|
| Aged | 24 | 2019 | 580 | 0.580 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 33 | 0.580 |
Why?
|
| Computing Methodologies | 1 | 2016 | 4 | 0.580 |
Why?
|
| Metagenomics | 1 | 2016 | 11 | 0.580 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2018 | 170 | 0.580 |
Why?
|
| Computer Simulation | 7 | 2020 | 96 | 0.570 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2019 | 23 | 0.570 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2023 | 173 | 0.560 |
Why?
|
| Epidemiology | 1 | 2015 | 1 | 0.540 |
Why?
|
| Geography | 4 | 2013 | 14 | 0.540 |
Why?
|
| Crohn Disease | 5 | 2013 | 16 | 0.520 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 3 | 2023 | 22 | 0.500 |
Why?
|
| Genomics | 4 | 2023 | 143 | 0.500 |
Why?
|
| Epilepsy | 3 | 2022 | 53 | 0.500 |
Why?
|
| Risk Factors | 14 | 2022 | 265 | 0.470 |
Why?
|
| Child | 13 | 2021 | 557 | 0.460 |
Why?
|
| Epilepsy, Generalized | 3 | 2021 | 21 | 0.450 |
Why?
|
| Homozygote | 3 | 2019 | 117 | 0.440 |
Why?
|
| Chronic Periodontitis | 5 | 2013 | 7 | 0.430 |
Why?
|
| Adolescent | 14 | 2021 | 493 | 0.420 |
Why?
|
| Longevity | 4 | 2017 | 40 | 0.410 |
Why?
|
| Whole Genome Sequencing | 3 | 2020 | 27 | 0.410 |
Why?
|
| Dupuytren Contracture | 3 | 2017 | 3 | 0.400 |
Why?
|
| Cohort Studies | 9 | 2021 | 191 | 0.400 |
Why?
|
| Artifacts | 1 | 2011 | 5 | 0.400 |
Why?
|
| Polymerase Chain Reaction | 3 | 2019 | 97 | 0.400 |
Why?
|
| Receptors, GABA-A | 3 | 2018 | 8 | 0.400 |
Why?
|
| Allelic Imbalance | 1 | 2011 | 2 | 0.390 |
Why?
|
| Young Adult | 12 | 2021 | 345 | 0.380 |
Why?
|
| Mutation, Missense | 4 | 2019 | 124 | 0.370 |
Why?
|
| Tandem Repeat Sequences | 1 | 2010 | 3 | 0.370 |
Why?
|
| Transcriptome | 2 | 2012 | 201 | 0.370 |
Why?
|
| Epidermis | 1 | 2009 | 6 | 0.360 |
Why?
|
| Intermediate Filament Proteins | 1 | 2009 | 6 | 0.360 |
Why?
|
| Exome | 5 | 2021 | 124 | 0.340 |
Why?
|
| Cell Differentiation | 1 | 2009 | 199 | 0.330 |
Why?
|
| Epilepsies, Partial | 2 | 2021 | 11 | 0.320 |
Why?
|
| Genetic Techniques | 1 | 2007 | 9 | 0.300 |
Why?
|
| Liver Cirrhosis, Alcoholic | 2 | 2018 | 2 | 0.300 |
Why?
|
| Essential Tremor | 3 | 2012 | 5 | 0.300 |
Why?
|
| Heterozygote | 4 | 2018 | 94 | 0.300 |
Why?
|
| Aged, 80 and over | 11 | 2018 | 206 | 0.300 |
Why?
|
| Child, Preschool | 8 | 2021 | 378 | 0.300 |
Why?
|
| Genotyping Techniques | 2 | 2017 | 28 | 0.300 |
Why?
|
| Postprandial Period | 5 | 2010 | 7 | 0.290 |
Why?
|
| Epilepsy, Rolandic | 2 | 2018 | 11 | 0.290 |
Why?
|
| Nerve Tissue Proteins | 3 | 2012 | 74 | 0.280 |
Why?
|
| Quantitative Trait, Heritable | 2 | 2020 | 14 | 0.280 |
Why?
|
| Periodontitis | 3 | 2010 | 8 | 0.270 |
Why?
|
| Selection, Genetic | 1 | 2005 | 38 | 0.270 |
Why?
|
| Alzheimer Disease | 2 | 2019 | 28 | 0.270 |
Why?
|
| Triglycerides | 4 | 2010 | 17 | 0.270 |
Why?
|
| Likelihood Functions | 3 | 2016 | 18 | 0.260 |
Why?
|
| Liver | 2 | 2017 | 61 | 0.260 |
Why?
|
| Quality Control | 4 | 2017 | 18 | 0.260 |
Why?
|
| Phylogeny | 3 | 2015 | 208 | 0.250 |
Why?
|
| Metabolic Syndrome | 3 | 2010 | 19 | 0.250 |
Why?
|
| Nod2 Signaling Adaptor Protein | 4 | 2019 | 6 | 0.250 |
Why?
|
| Bayes Theorem | 2 | 2022 | 42 | 0.250 |
Why?
|
| Biomarkers | 4 | 2018 | 188 | 0.240 |
Why?
|
| Colitis, Ulcerative | 4 | 2013 | 13 | 0.240 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 210 | 0.240 |
Why?
|
| Lipid Metabolism | 2 | 2017 | 25 | 0.230 |
Why?
|
| Genetic Testing | 3 | 2020 | 66 | 0.230 |
Why?
|
| Abnormalities, Multiple | 2 | 2018 | 86 | 0.230 |
Why?
|
| Seizures | 1 | 2023 | 24 | 0.230 |
Why?
|
| Gene-Environment Interaction | 2 | 2012 | 23 | 0.220 |
Why?
|
| Smoking | 2 | 2012 | 14 | 0.210 |
Why?
|
| Models, Statistical | 2 | 2020 | 46 | 0.210 |
Why?
|
| Neoplasms | 2 | 2015 | 135 | 0.210 |
Why?
|
| Gallstones | 2 | 2013 | 8 | 0.210 |
Why?
|
| Cleft Lip | 1 | 2022 | 95 | 0.210 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2013 | 16 | 0.210 |
Why?
|
| Cleft Palate | 1 | 2022 | 103 | 0.210 |
Why?
|
| Odds Ratio | 5 | 2018 | 40 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2012 | 8 | 0.200 |
Why?
|
| beta-Defensins | 2 | 2012 | 3 | 0.200 |
Why?
|
| Insulin | 4 | 2010 | 61 | 0.200 |
Why?
|
| Butyrophilins | 1 | 2021 | 1 | 0.200 |
Why?
|
| Berylliosis | 1 | 2021 | 1 | 0.200 |
Why?
|
| Beryllium | 1 | 2021 | 1 | 0.200 |
Why?
|
| Occupational Exposure | 1 | 2021 | 4 | 0.200 |
Why?
|
| Hearing Loss | 1 | 2021 | 5 | 0.200 |
Why?
|
| Interleukin-10 | 2 | 2013 | 12 | 0.200 |
Why?
|
| Tobacco Use Disorder | 1 | 2020 | 4 | 0.200 |
Why?
|
| Machine Learning | 1 | 2021 | 27 | 0.200 |
Why?
|
| Polymorphism, Genetic | 4 | 2012 | 68 | 0.190 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2018 | 23 | 0.190 |
Why?
|
| Genetic Carrier Screening | 2 | 2018 | 7 | 0.190 |
Why?
|
| Pedigree | 6 | 2021 | 304 | 0.190 |
Why?
|
| France | 1 | 2020 | 3 | 0.190 |
Why?
|
| Databases, Genetic | 2 | 2018 | 62 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 2 | 2010 | 5 | 0.180 |
Why?
|
| RNA, Antisense | 2 | 2010 | 5 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2011 | 25 | 0.180 |
Why?
|
| Czech Republic | 2 | 2016 | 4 | 0.180 |
Why?
|
| NADPH Oxidase 1 | 1 | 2019 | 1 | 0.170 |
Why?
|
| NADPH Oxidases | 1 | 2019 | 2 | 0.170 |
Why?
|
| Infant | 4 | 2018 | 267 | 0.170 |
Why?
|
| CpG Islands | 1 | 2019 | 51 | 0.170 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2018 | 1 | 0.170 |
Why?
|
| Survival of Motor Neuron 1 Protein | 1 | 2018 | 4 | 0.170 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2018 | 4 | 0.170 |
Why?
|
| Microfilament Proteins | 1 | 2018 | 17 | 0.170 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2018 | 12 | 0.170 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 33 | 0.170 |
Why?
|
| Gene Expression | 2 | 2016 | 138 | 0.160 |
Why?
|
| Coronary Disease | 2 | 2009 | 16 | 0.160 |
Why?
|
| DNA, Ancient | 1 | 2018 | 10 | 0.160 |
Why?
|
| Leprosy | 1 | 2018 | 5 | 0.160 |
Why?
|
| BRCA2 Protein | 1 | 2018 | 14 | 0.160 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 19 | 0.160 |
Why?
|
| Logistic Models | 6 | 2021 | 26 | 0.160 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 11 | 0.160 |
Why?
|
| Acrocallosal Syndrome | 1 | 2018 | 1 | 0.160 |
Why?
|
| Mutation Rate | 1 | 2018 | 16 | 0.160 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2018 | 9 | 0.160 |
Why?
|
| Cerebellum | 1 | 2018 | 16 | 0.160 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2017 | 3 | 0.160 |
Why?
|
| Hedgehog Proteins | 1 | 2018 | 13 | 0.160 |
Why?
|
| Eye Abnormalities | 1 | 2018 | 15 | 0.160 |
Why?
|
| Loss of Function Mutation | 1 | 2018 | 29 | 0.160 |
Why?
|
| Fibrosis | 1 | 2017 | 8 | 0.160 |
Why?
|
| Genetic Association Studies | 3 | 2017 | 122 | 0.160 |
Why?
|
| Retina | 1 | 2018 | 26 | 0.160 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2017 | 1 | 0.150 |
Why?
|
| China | 1 | 2017 | 11 | 0.150 |
Why?
|
| Slovakia | 1 | 2016 | 3 | 0.150 |
Why?
|
| Promoter Regions, Genetic | 2 | 2007 | 99 | 0.150 |
Why?
|
| Alopecia | 1 | 2017 | 35 | 0.150 |
Why?
|
| Schizophrenia | 2 | 2020 | 74 | 0.150 |
Why?
|
| Blood Glucose | 4 | 2010 | 59 | 0.150 |
Why?
|
| Chorea | 1 | 2016 | 3 | 0.140 |
Why?
|
| Epilepsy, Benign Neonatal | 1 | 2016 | 3 | 0.140 |
Why?
|
| NAV1.6 Voltage-Gated Sodium Channel | 1 | 2016 | 3 | 0.140 |
Why?
|
| Wnt Proteins | 2 | 2017 | 17 | 0.140 |
Why?
|
| Myotonia Congenita | 1 | 2016 | 2 | 0.140 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type IIc | 1 | 2016 | 2 | 0.140 |
Why?
|
| Selenoproteins | 1 | 2016 | 2 | 0.140 |
Why?
|
| Rickets, Hypophosphatemic | 1 | 2016 | 2 | 0.140 |
Why?
|
| South America | 2 | 2013 | 2 | 0.140 |
Why?
|
| Muscle Proteins | 1 | 2016 | 11 | 0.140 |
Why?
|
| DNA Repair | 1 | 2016 | 60 | 0.140 |
Why?
|
| Lipase | 1 | 2015 | 8 | 0.140 |
Why?
|
| Acyltransferases | 1 | 2015 | 11 | 0.140 |
Why?
|
| Population Groups | 2 | 2013 | 2 | 0.140 |
Why?
|
| Software Validation | 1 | 2015 | 1 | 0.140 |
Why?
|
| DNA, Neoplasm | 2 | 2015 | 23 | 0.140 |
Why?
|
| DNA Damage | 1 | 2016 | 77 | 0.130 |
Why?
|
| Penetrance | 1 | 2015 | 15 | 0.130 |
Why?
|
| Cholesterol | 2 | 2013 | 22 | 0.130 |
Why?
|
| Lipoylation | 1 | 2015 | 2 | 0.130 |
Why?
|
| Kv1.2 Potassium Channel | 1 | 2015 | 1 | 0.130 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 92 | 0.130 |
Why?
|
| Spasms, Infantile | 1 | 2015 | 4 | 0.130 |
Why?
|
| Fasting | 3 | 2010 | 19 | 0.130 |
Why?
|
| Quantitative Trait Loci | 3 | 2013 | 90 | 0.130 |
Why?
|
| Cell Line | 5 | 2013 | 137 | 0.130 |
Why?
|
| Apolipoproteins E | 2 | 2011 | 12 | 0.120 |
Why?
|
| Carrier Proteins | 2 | 2012 | 65 | 0.120 |
Why?
|
| Hemochromatosis | 1 | 2014 | 1 | 0.120 |
Why?
|
| Subtilisins | 1 | 2014 | 1 | 0.120 |
Why?
|
| Liver Cirrhosis | 1 | 2014 | 9 | 0.120 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2014 | 10 | 0.120 |
Why?
|
| Dicarboxylic Acids | 1 | 2013 | 1 | 0.120 |
Why?
|
| Phosphorylcholine | 1 | 2013 | 1 | 0.120 |
Why?
|
| Electrosurgery | 1 | 2013 | 2 | 0.120 |
Why?
|
| Fatty Liver | 1 | 2013 | 8 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2015 | 138 | 0.120 |
Why?
|
| Wound Healing | 1 | 2013 | 9 | 0.120 |
Why?
|
| Metabolome | 1 | 2013 | 18 | 0.120 |
Why?
|
| Central America | 1 | 2013 | 1 | 0.120 |
Why?
|
| Linguistics | 1 | 2013 | 2 | 0.120 |
Why?
|
| Interleukin-12 Receptor beta 1 Subunit | 1 | 2013 | 1 | 0.120 |
Why?
|
| Language | 1 | 2013 | 7 | 0.120 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2013 | 7 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2010 | 11 | 0.110 |
Why?
|
| Lipoproteins | 1 | 2013 | 1 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2013 | 48 | 0.110 |
Why?
|
| RNA, Long Noncoding | 1 | 2013 | 36 | 0.110 |
Why?
|
| Pancreatitis, Chronic | 1 | 2012 | 2 | 0.110 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2012 | 6 | 0.110 |
Why?
|
| Endosonography | 1 | 2012 | 1 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 13 | 0.110 |
Why?
|
| Gastroscopy | 1 | 2012 | 2 | 0.110 |
Why?
|
| Stomach Neoplasms | 1 | 2012 | 5 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2012 | 25 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2010 | 13 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 27 | 0.110 |
Why?
|
| Peptide Chain Initiation, Translational | 1 | 2012 | 5 | 0.110 |
Why?
|
| Ribosomes | 1 | 2012 | 9 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2012 | 14 | 0.110 |
Why?
|
| Glutamate Plasma Membrane Transport Proteins | 1 | 2012 | 1 | 0.110 |
Why?
|
| Open Reading Frames | 1 | 2012 | 33 | 0.110 |
Why?
|
| Nod1 Signaling Adaptor Protein | 2 | 2009 | 2 | 0.110 |
Why?
|
| Sensory Gating | 1 | 2012 | 3 | 0.110 |
Why?
|
| Psoriasis | 1 | 2012 | 9 | 0.110 |
Why?
|
| Phosphatidate Phosphatase | 1 | 2012 | 1 | 0.110 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2012 | 5 | 0.110 |
Why?
|
| Lipogenesis | 1 | 2012 | 3 | 0.110 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2012 | 4 | 0.110 |
Why?
|
| Lipids | 1 | 2012 | 26 | 0.110 |
Why?
|
| Chronic Disease | 3 | 2021 | 20 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2008 | 15 | 0.100 |
Why?
|
| Entropy | 3 | 2007 | 4 | 0.100 |
Why?
|
| Obesity | 1 | 2012 | 86 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 73 | 0.100 |
Why?
|
| Human Genome Project | 1 | 2011 | 1 | 0.100 |
Why?
|
| Netherlands | 4 | 2013 | 25 | 0.100 |
Why?
|
| GABA Plasma Membrane Transport Proteins | 1 | 2010 | 1 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 17 | 0.100 |
Why?
|
| Bacterial Infections | 1 | 2010 | 3 | 0.100 |
Why?
|
| Bilirubin | 1 | 2010 | 1 | 0.100 |
Why?
|
| Gilbert Disease | 1 | 2010 | 1 | 0.100 |
Why?
|
| Organic Anion Transporters | 1 | 2010 | 3 | 0.100 |
Why?
|
| Glucuronosyltransferase | 1 | 2010 | 4 | 0.100 |
Why?
|
| Receptors, Interleukin | 1 | 2010 | 4 | 0.100 |
Why?
|
| Iran | 2 | 2021 | 7 | 0.100 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2010 | 14 | 0.100 |
Why?
|
| Parkinson Disease | 1 | 2010 | 26 | 0.090 |
Why?
|
| Chromosomes, Human | 1 | 2010 | 12 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 93 | 0.090 |
Why?
|
| Myocardial Infarction | 2 | 2007 | 28 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2007 | 50 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2010 | 31 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 1 | 2010 | 3 | 0.090 |
Why?
|
| alpha-Macroglobulins | 1 | 2010 | 1 | 0.090 |
Why?
|
| Biliary Tract | 1 | 2009 | 3 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2012 | 256 | 0.090 |
Why?
|
| Models, Molecular | 3 | 2018 | 50 | 0.090 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2009 | 8 | 0.090 |
Why?
|
| 3' Untranslated Regions | 1 | 2009 | 22 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2009 | 4 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 13 | 0.090 |
Why?
|
| HIV Infections | 1 | 2009 | 11 | 0.090 |
Why?
|
| HIV-1 | 1 | 2009 | 12 | 0.090 |
Why?
|
| User-Computer Interface | 1 | 2009 | 19 | 0.090 |
Why?
|
| Internet | 1 | 2009 | 19 | 0.090 |
Why?
|
| Matched-Pair Analysis | 1 | 2009 | 1 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2009 | 13 | 0.090 |
Why?
|
| Actin-Related Protein 2-3 Complex | 1 | 2008 | 1 | 0.080 |
Why?
|
| Interleukin-1 | 1 | 2008 | 6 | 0.080 |
Why?
|
| Annexins | 1 | 2008 | 1 | 0.080 |
Why?
|
| Inflammation | 1 | 2010 | 179 | 0.080 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 45 | 0.080 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 2 | 0.080 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2008 | 9 | 0.080 |
Why?
|
| Multigene Family | 1 | 2008 | 30 | 0.080 |
Why?
|
| Diet | 1 | 2008 | 12 | 0.080 |
Why?
|
| Receptors, CCR5 | 1 | 2008 | 3 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2008 | 9 | 0.080 |
Why?
|
| RNA, Messenger | 3 | 2017 | 263 | 0.080 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2007 | 1 | 0.080 |
Why?
|
| Animals | 3 | 2018 | 1545 | 0.080 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2007 | 13 | 0.080 |
Why?
|
| Dietary Fats | 1 | 2007 | 10 | 0.080 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2007 | 5 | 0.080 |
Why?
|
| Hyperlipidemias | 1 | 2007 | 4 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2007 | 6 | 0.080 |
Why?
|
| PPAR gamma | 1 | 2007 | 8 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2007 | 51 | 0.080 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2007 | 16 | 0.080 |
Why?
|
| Adiponectin | 1 | 2007 | 30 | 0.080 |
Why?
|
| Cells, Cultured | 2 | 2018 | 261 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 52 | 0.070 |
Why?
|
| Hypertension | 2 | 2007 | 15 | 0.070 |
Why?
|
| Austria | 2 | 2018 | 4 | 0.070 |
Why?
|
| Exons | 3 | 2012 | 97 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2022 | 139 | 0.070 |
Why?
|
| Confidence Intervals | 2 | 2018 | 3 | 0.070 |
Why?
|
| Prognosis | 2 | 2018 | 196 | 0.070 |
Why?
|
| Incidence | 2 | 2018 | 54 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2018 | 47 | 0.060 |
Why?
|
| Glucose Tolerance Test | 3 | 2010 | 20 | 0.060 |
Why?
|
| Middle East | 1 | 2023 | 3 | 0.060 |
Why?
|
| Biophysics | 1 | 2023 | 1 | 0.060 |
Why?
|
| Virulence | 1 | 2023 | 14 | 0.060 |
Why?
|
| Trans-Activators | 2 | 2017 | 25 | 0.060 |
Why?
|
| Binding Sites | 2 | 2013 | 73 | 0.060 |
Why?
|
| Genetic Pleiotropy | 1 | 2022 | 4 | 0.050 |
Why?
|
| Tourette Syndrome | 1 | 2002 | 1 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 345 | 0.050 |
Why?
|
| Syndrome | 2 | 2015 | 91 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2015 | 186 | 0.050 |
Why?
|
| Americas | 1 | 2021 | 1 | 0.050 |
Why?
|
| Oceania | 1 | 2021 | 1 | 0.050 |
Why?
|
| Africa | 1 | 2021 | 2 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2021 | 16 | 0.050 |
Why?
|
| Ecuador | 1 | 2020 | 3 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2012 | 174 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 21 | 0.050 |
Why?
|
| Inheritance Patterns | 1 | 2020 | 10 | 0.050 |
Why?
|
| Molecular Sequence Annotation | 1 | 2020 | 21 | 0.050 |
Why?
|
| Amino Acid Substitution | 2 | 2013 | 45 | 0.050 |
Why?
|
| Macular Degeneration | 1 | 2020 | 1 | 0.050 |
Why?
|
| Base Sequence | 2 | 2013 | 275 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 11 | 0.050 |
Why?
|
| Consanguinity | 1 | 2019 | 56 | 0.040 |
Why?
|
| Disease Progression | 2 | 2009 | 72 | 0.040 |
Why?
|
| Age Distribution | 1 | 2018 | 5 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2018 | 5 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 7 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 161 | 0.040 |
Why?
|
| International Cooperation | 1 | 2018 | 7 | 0.040 |
Why?
|
| Family Health | 1 | 2018 | 24 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 78 | 0.040 |
Why?
|
| Denmark | 1 | 2018 | 10 | 0.040 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2018 | 8 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2018 | 11 | 0.040 |
Why?
|
| HLA-DRB1 Chains | 1 | 2018 | 11 | 0.040 |
Why?
|
| Mycobacterium leprae | 1 | 2018 | 6 | 0.040 |
Why?
|
| Fossils | 1 | 2018 | 7 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2018 | 149 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2018 | 119 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 40 | 0.040 |
Why?
|
| Chick Embryo | 1 | 2018 | 1 | 0.040 |
Why?
|
| Serum Response Factor | 1 | 2017 | 3 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 11 | 0.040 |
Why?
|
| CCCTC-Binding Factor | 1 | 2017 | 10 | 0.040 |
Why?
|
| Genome, Bacterial | 1 | 2018 | 50 | 0.040 |
Why?
|
| Age Factors | 1 | 2017 | 56 | 0.040 |
Why?
|
| Myofibroblasts | 1 | 2017 | 2 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 1998 | 46 | 0.040 |
Why?
|
| Introns | 1 | 2017 | 60 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2018 | 52 | 0.040 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2007 | 6 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2017 | 37 | 0.040 |
Why?
|
| Expert Systems | 1 | 2017 | 2 | 0.040 |
Why?
|
| Self Report | 1 | 2017 | 3 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2017 | 3 | 0.040 |
Why?
|
| Glutamic Acid | 1 | 2017 | 11 | 0.040 |
Why?
|
| Dipeptides | 1 | 2017 | 2 | 0.040 |
Why?
|
| Melatonin | 1 | 2017 | 1 | 0.040 |
Why?
|
| Fibroblast Growth Factor 5 | 1 | 2017 | 1 | 0.040 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2017 | 3 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 15 | 0.040 |
Why?
|
| Adipogenesis | 1 | 2017 | 5 | 0.040 |
Why?
|
| Interferon Regulatory Factors | 1 | 2017 | 19 | 0.040 |
Why?
|
| Metabolomics | 1 | 2017 | 24 | 0.040 |
Why?
|
| Genetics, Medical | 1 | 2017 | 4 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 23 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 65 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 64 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 103 | 0.040 |
Why?
|
| Mice | 1 | 2018 | 737 | 0.040 |
Why?
|
| Rare Diseases | 1 | 2016 | 9 | 0.030 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2015 | 5 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 13 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2015 | 22 | 0.030 |
Why?
|
| Landau-Kleffner Syndrome | 1 | 2015 | 2 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2015 | 64 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 312 | 0.030 |
Why?
|
| Hemochromatosis Protein | 1 | 2014 | 1 | 0.030 |
Why?
|
| Iron | 1 | 2014 | 14 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2013 | 2 | 0.030 |
Why?
|
| Dissection | 1 | 2013 | 1 | 0.030 |
Why?
|
| Hepatic Stellate Cells | 1 | 2013 | 3 | 0.030 |
Why?
|
| Lipid Peroxidation | 1 | 2013 | 8 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 38 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 22 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 43 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2013 | 30 | 0.030 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2013 | 1 | 0.030 |
Why?
|
| Turkey | 1 | 2013 | 13 | 0.030 |
Why?
|
| Italy | 1 | 2013 | 32 | 0.030 |
Why?
|
| Apoptosis | 1 | 2013 | 94 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2013 | 28 | 0.030 |
Why?
|
| Survival Rate | 1 | 2012 | 36 | 0.030 |
Why?
|
| Puromycin | 1 | 2012 | 1 | 0.030 |
Why?
|
| Codon, Initiator | 1 | 2012 | 2 | 0.030 |
Why?
|
| 5' Untranslated Regions | 1 | 2012 | 6 | 0.030 |
Why?
|
| Sweden | 1 | 2012 | 9 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 66 | 0.030 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2012 | 1 | 0.030 |
Why?
|
| Acute Disease | 1 | 2012 | 17 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2012 | 44 | 0.030 |
Why?
|
| Cotinine | 1 | 2012 | 2 | 0.030 |
Why?
|
| Transcription Factor 4 | 1 | 2012 | 4 | 0.030 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2012 | 3 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2012 | 13 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2012 | 20 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2012 | 5 | 0.030 |
Why?
|
| Fibroblast Growth Factor 6 | 1 | 2011 | 1 | 0.030 |
Why?
|
| Sulfotransferases | 1 | 2011 | 2 | 0.030 |
Why?
|
| snRNP Core Proteins | 1 | 2011 | 4 | 0.030 |
Why?
|
| Lymphoma, Follicular | 1 | 2011 | 9 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 7 | 0.030 |
Why?
|
| Sulfites | 1 | 2011 | 5 | 0.030 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2011 | 2 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2010 | 8 | 0.020 |
Why?
|
| Streptococcus gordonii | 1 | 2010 | 1 | 0.020 |
Why?
|
| Porphyromonas gingivalis | 1 | 2010 | 2 | 0.020 |
Why?
|
| Gingiva | 1 | 2010 | 2 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2010 | 5 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2010 | 62 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2010 | 71 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2010 | 47 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 2 | 0.020 |
Why?
|
| Anthropometry | 1 | 2010 | 5 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 20 | 0.020 |
Why?
|
| Glypicans | 1 | 2009 | 1 | 0.020 |
Why?
|
| Bile | 1 | 2009 | 3 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2010 | 29 | 0.020 |
Why?
|
| GATA3 Transcription Factor | 1 | 2009 | 4 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2009 | 21 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2009 | 30 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 29 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 35 | 0.020 |
Why?
|
| Asthma | 1 | 2009 | 6 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 122 | 0.020 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2009 | 3 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2009 | 24 | 0.020 |
Why?
|
| Receptors, Nicotinic | 1 | 2009 | 5 | 0.020 |
Why?
|
| Research Design | 1 | 2009 | 9 | 0.020 |
Why?
|
| Selectins | 1 | 2008 | 1 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2008 | 3 | 0.020 |
Why?
|
| Health | 1 | 2008 | 3 | 0.020 |
Why?
|
| Solubility | 1 | 2008 | 7 | 0.020 |
Why?
|
| Sequence Analysis, Protein | 1 | 2008 | 9 | 0.020 |
Why?
|
| Prevalence | 1 | 2008 | 46 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2009 | 99 | 0.020 |
Why?
|
| HLA-DP Antigens | 1 | 2007 | 1 | 0.020 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2007 | 1 | 0.020 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2007 | 1 | 0.020 |
Why?
|
| HLA-DP beta-Chains | 1 | 2007 | 3 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2007 | 3 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2007 | 15 | 0.020 |
Why?
|
| NLR Proteins | 1 | 2007 | 2 | 0.020 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2007 | 4 | 0.020 |
Why?
|
| Overweight | 1 | 2007 | 4 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2007 | 5 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2007 | 8 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 14 | 0.020 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2007 | 9 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 30 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2007 | 14 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2007 | 13 | 0.020 |
Why?
|
| Body Size | 1 | 2007 | 3 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 30 | 0.020 |
Why?
|
| Glycine | 1 | 2007 | 2 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2007 | 6 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2007 | 38 | 0.020 |
Why?
|
| Receptors, CCR4 | 1 | 2006 | 1 | 0.020 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2006 | 2 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2006 | 8 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2007 | 64 | 0.020 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 1998 | 1 | 0.010 |
Why?
|
| Databases as Topic | 1 | 1998 | 1 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 1998 | 2 | 0.010 |
Why?
|
| Automation | 1 | 1998 | 3 | 0.010 |
Why?
|
